The aging striatal dopamine function

Parkinsonism and Related Disorders

Volumn 18, Issue 5, 2012, Pages 426-432

  Darbin, Olivier ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

Catecholamine; Dopamine depletion; Elderly; Motor activity; Nigro striatal pathway

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AGING; BASAL GANGLION; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DOWN REGULATION; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYNAPSE; UPREGULATION;

AGING; CORPUS STRIATUM; DOPAMINE; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; RECEPTORS, DOPAMINE;

EID: 84861201258     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.11.025     Document Type: Review

References (101)

1. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M., et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996, 334:71-76.
2. Ingram D.K. Age-related decline in physical activity: generalization to nonhumans. Med Sci Sports Exerc 2000, 32:1623-1629.
3. Wilson R.S., Schneider J.A., Beckett L.A., Evans D.A., Bennett D.A. Progression of gait disorder and rigidity and risk of death in older persons. Neurology 2002, 58:1815-1819.
4. Larsson L., Ramamurthy B. Aging-related changes in skeletal muscle. Mechanisms and interventions. Drugs Aging 2000, 17:303-316.
5. Dickstein D.L., Kabaso D., Rocher A.B., Luebke J.I., Wearne S.L., Hof P.R. Changes in the structural complexity of the aged brain. Aging Cell 2007, 6:275-284.
6. Middleton F.A., Strick P.L. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Brain Res Rev 2000, 31:236-250.
7. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990, 13:266-271.
8. Delong M.R. Primate models of movement-disorders of basal ganglia origin. Trends Neurosci 1990, 13:281-285.
9. Turner R.S., Grafton S.T., Votaw J.R., Delong M.R., Hoffman J.M. Motor subcircuits mediating the control of movement velocity: a PET study. J Neurophysiol 1998, 80:2162-2176.
10. Obeso J.A., Rodriguez M.C., DeLong M.R. Basal ganglia pathophysiology. A critical review. Adv Neurol 1997, 74:3-18.
11. Saint-Cyr J.A. Basal ganglia: functional perspectives and behavioral domains. Adv Neurol 2005, 96:1-16.
12. Cruz-Muros I., Afonso-Oramas D., Abreu P., Barroso-Chinea P., Rodriguez M., Gonzalez M.C., et al. Aging of the rat mesostriatal system: differences between the nigrostriatal and the mesolimbic compartments. Exp Neurol 2007, 204:147-161.
13. Haycock J.W., Becker L., Ang L., Furukawa Y., Hornykiewicz O., Kish S.J. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 2003, 87:574-585.
14. Kish S.J., Shannak K., Rajput A., Deck J.H., Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992, 58:642-648.
15. Lloyd K.G., Hornykiewicz O. Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem 1972, 19:1549-1559.
16. Harada N., Nishiyama S., Satoh K., Fukumoto D., Kakiuchi T., Tsukada H. Age-related changes in the striatal dopaminergic system in the living brain: a multiparametric PET study in conscious monkeys. Synapse 2002, 45:38-45.
17. Suzuki M., Hatano K., Sakiyama Y., Kawasumi Y., Kato T., Ito K. Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography. Synapse 2001, 41:285-293.
18. Wang Y., Chan G.L., Holden J.E., Dobko T., Mak E., Schulzer M., et al. Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 1998, 30:56-61.
19. Giorgi O., De Montis G., Porceddu M.L., Mele S., Calderini G., Toffano G., et al. Developmental and age-related changes in D1-dopamine receptors and dopamine content in the rat striatum. Brain Res 1987, 432:283-290.
20. Stark A.K., Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res 2004, 318:81-92.
21. Ota M., Yasuno F., Ito H., Seki C., Nozaki S., Asada T., et al. Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[beta-11C]DOPA. Life Sci 2006, 79:730-736.
22. Ishida Y., Okawa Y., Ito S., Shirokawa T., Isobe K. Age-dependent changes in dopaminergic projections from the substantia nigra pars compacta to the neostriatum. Neurosci Lett 2007, 418:257-261.
23. McCormack A.L., Di Monte D.A., Delfani K., Irwin I., DeLanney L.E., Langston W.J., et al. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 2004, 471:387-395.
24. Colebrooke R.E., Humby T., Lynch P.J., McGowan D.P., Xia J., Emson P.C. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur J Neurosci 2006, 24:2622-2630.
25. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
26. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 1998, 401:253-265.
27. Barili P., De Carolis G., Zaccheo D., Amenta F. Sensitivity to ageing of the limbic dopaminergic system: a review. Mech Ageing Dev 1998, 106:57-92.
28. Reeves S., Bench C., Howard R. Ageing and the nigrostriatal dopaminergic system. Int J Geriatr Psychiatry 2002, 17:359-370.
29. Smith C.D., Chebrolu H., Wekstein D.R., Schmitt F.A., Markesbery W.R. Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiol Aging 2007, 28:1075-1087.
30. Gunning-Dixon F.M., Head D., McQuain J., Acker J.D., Raz N. Differential aging of the human striatum: a prospective MR imaging study. AJNR Am J Neuroradiol 1998, 19:1501-1507.
31. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001, 14:21-36.
32. Raz N., Gunning-Dixon F.M., Head D., Dupuis J.H., Acker J.D. Neuroanatomical correlates of cognitive aging: evidence from structural magnetic resonance imaging. Neuropsychology 1998, 12:95-114.
33. Pakkenberg H., Andersen B.B., Burns R.S., Pakkenberg B. A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res 1995, 693:201-206.
34. Kubis N., Faucheux B.A., Ransmayr G., Damier P., Duyckaerts C., Henin D., et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000, 123:366-373.
35. McNeill T.H., Koek L.L. Differential effects of advancing age on neurotransmitter cell loss in the substantia nigra and striatum of C57BL/6N mice. Brain Res 1990, 521:107-117.
36. Emerich D.F., McDermott P., Krueger P., Banks M., Zhao J., Marszalkowski J., et al. Locomotion of aged rats: relationship to neurochemical but not morphological changes in nigrostriatal dopaminergic neurons. Brain Res Bull 1993, 32:477-486.
37. Irwin I., DeLanney L.E., McNeill T., Chan P., Forno L.S., Murphy G.M., et al. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 1994, 3:251-265.
38. Salvatore M.F., Apparsundaram S., Gerhardt G.A. Decreased plasma membrane expression of striatal dopamine transporter in aging. Neurobiol Aging 2003, 24:1147-1154.
39. McGeer P.L., McGeer E.G., Suzuki J.S. Aging and extrapyramidal function. Arch Neurol 1977, 34:33-35.
40. Mann D.M., Yates P.O. The effects of ageing on the pigmented nerve cells of the human locus caeruleous and substantia nigra. Acta Neuropathol 1979, 47:93-97.
41. Thiessen B., Rajput A.H., Laverty W., Desai H. Age, environments, and the number of substantia nigra neurons. Adv Neurol 1990, 53:201-206.
42. Ma S.Y., Roytt M., Collan Y., Rinne J.O. Unbiased morphometrical measurements show loss of pigmented nigral neurones with ageing. Neuropathol Appl Neurobiol 1999, 25:394-399.
43. Siddiqi Z., Kemper T.L., Killiany R. Age-related neuronal loss from the substantia nigra-pars compacta and ventral tegmental area of the rhesus monkey. J Neuropathol Exp Neurol 1999, 58:959-971.
44. Cabello C.R., Thune J.J., Pakkenberg H., Pakkenberg B. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002, 28:283-291.
45. Chu Y., Kompoliti K., Cochran E.J., Mufson E.J., Kordower J.H. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol 2002, 450:203-214.
46. Vaillancourt D.E., Spraker M.B., Prodoehl J., Zhou X.J., Little D.M. Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. Neurobiol Aging 2010.
47. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973, 20:415-455.
48. Miguez J.M., Aldegunde M., Paz-Valinas L., Recio J., Sanchez-Barcelo E. Selective changes in the contents of noradrenaline, dopamine and serotonin in rat brain areas during aging. J Neural Transm 1999, 106:1089-1098.
49. Udenfriend S. Tyrosine hydroxylase. Pharmacol Rev 1966, 18:43-51.
50. Yurek D.M., Hipkens S.B., Hebert M.A., Gash D.M., Gerhardt G.A. Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats. Brain Res 1998, 791:246-256.
51. Gerhardt G.A., Cass W.A., Yi A., Zhang Z., Gash D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 2002, 80:168-177.
52. Hurley P.J., Elsworth J.D., Whittaker M.C., Roth R.H., Redmond D.E. Aged monkeys as a partial model for Parkinson's disease. Pharmacol Biochem Behav 2011, 99:324-332.
53. Gozlan H., Daval G., Verge D., Spampinato U., Fattaccini C.M., Gallissot M.C., et al. Aging associated changes in serotoninergic and dopaminergic pre- and postsynaptic neurochemical markers in the rat brain. Neurobiol Aging 1990, 11:437-449.
54. Dluzen D.E., McDermott J.L., Ramirez V.D. Changes in dopamine release in vitro from the corpus striatum of young versus aged rats as a function of infusion modes of L-dopa, potassium, and amphetamine. Exp Neurol 1991, 112:153-160.
55. Joseph J.A., Dalton T.K., Hunt W.A. Age-related decrements in the muscarinic enhancement of K+-evoked release of endogenous striatal dopamine: an indicator of altered cholinergic-dopaminergic reciprocal inhibitory control in senescence. Brain Res 1988, 454:140-148.
56. Nakano M., Mizuno T. Age-related changes in the metabolism of neurotransmitters in rat striatum: a microdialysis study. Mech Ageing Dev 1996, 86:95-104.
57. Rose G.M., Gerhardt G.A., Conboy G.L., Hoffer B.J. Age-related alterations in monoamine release from rat striatum: an in vivo electrochemical study. Neurobiol Aging 1986, 7:77-82.
58. Santiago M., Machado A., Cano J. Effects of age and dopamine agonists and antagonists on striatal dopamine release in the rat: an in vivo microdialysis study. Mech Ageing Dev 1993, 67:261-267.
59. Gerhardt G.A., Cass W.A., Henson M., Zhang Z., Ovadia A., Hoffer B.J., et al. Age-related changes in potassium-evoked overflow of dopamine in the striatum of the Rhesus monkey. Neurobiol Aging 1995, 16:939-946.
60. Levitt M., Spector S., Sjoerdsma A., Udenfriend S. Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea-pig heart. J Pharmacol Exp Ther 1965, 148:1-8.
61. Martin W.R.W., Palmer M.R., Patlak C.S., Calne D.B. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989, 26:535-542.
62. Cordes M., Snow B.J., Cooper S., Schulzer M., Pate B.D., Ruth T.J., et al. Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren. Ann Neurol 1994, 36:667-670.
63. Sossi V., de la Fuente-Fernandez R., Schulzer M., Troiano A.R., Ruth T.J., Stoessl A.J. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007, 62:468-474.
64. Biju G., de la Fuente-Fernandez R. Dopaminergic function and progression of Parkinson's disease: PET findings. Parkinsonism Relat Disord 2009, 15(Suppl. 4):S38-S40.
65. 3H]WIN 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the fischer 344 rat. J Pharmacol Exp Ther 1999, 288:1334-1339.
66. 3H]dopamine uptake in rat striatum during aging. J Neurochem 1991, 56:575-579.
67. Erixon-Lindroth N., Farde L., Wahlin T.B., Sovago J., Halldin C., Backman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res 2005, 138:1-12.
68. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Zoghbi S.S., Baldwin R.M., et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002, 10:36-43.
69. Cruz-Muros I., Afonso-Oramas D., Abreu P., Perez-Delgado M.M., Rodriguez M., Gonzalez-Hernandez T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol Aging 2007.
70. Mozley L.H., Gur R.C., Mozley P.D., Gur R.E. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001, 158:1492-1499.
71. Friedemann M.N., Gerhardt G.A. Regional effects of aging on dopaminergic function in the Fischer-344 rat. Neurobiol Aging 1992, 13:325-332.
72. Hebert M.A., Gerhardt G.A. Age-related changes in the capacity, rate, and modulation of dopamine uptake within the striatum and nucleus accumbens of Fischer 344 rats: an in vivo electrochemical study. J Pharmacol Exp Ther 1999, 288:879-887.
73. Elsworth J.D., Brittan M.S., Taylor J.R., Sladek J.R., Redmond D.E., Innis R.B., et al. Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study. Brain Res 1998, 795:55-62.
74. Morissette M., Goulet M., Calon F., Falardeau P., Blanchet P.J., Bedard P.J., et al. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine. Mol Pharmacol 1996, 50:1073-1079.
75. Rinne J.O., Laihinen A., Ruottinen H., Ruotsalainen U., Nagren K., Lehikoinen P., et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. J Neurol Sci 1995, 132:156-161.
76. Gagnon C., Gomez-Mancilla B., Markstein R., Bedard P.J., Di Paolo T. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors. Prog Neuropsychopharmacol Biol Psychiatry 1995, 19:667-676.
77. Yokochi M. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease. Parkinsonism Relat Disord 2009, 15(Suppl. 1):S25-S30.
78. Newman R.P., LeWitt P.A., Jaffe M., Calne D.B., Larsen T.A. Motor function in the normal aging population: treatment with levodopa. Neurology 1985, 35:571-573.
79. Willemssen R., Falkenstein M., Schwarz M., Muller T., Beste C. Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control. Neurobiol Aging 2011, 32:327-335.
80. White N.J., Barnes T.R. Senile parkinsonism, a study of current treatment. Age Ageing 1981, 10:81-86.
81. Diederich N.J., Moore C.G., Leurgans S.E., Chmura T.A., Goetz C.G. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol 2003, 60:529-533.
82. Frank C., Pari G., Rossiter J.P. Approach to diagnosis of Parkinson disease. Can Fam Physician 2006, 52:862-868.
83. Zhang Z., Andersen A., Grondin R., Barber T., Avison R., Gerhardt G., et al. Pharmacological MRI mapping of age-associated changes in basal ganglia circuitry of awake Rhesus monkeys. NeuroImage 2001, 14:1159-1167.
84. Ingram D.K., Ikari H., Umegaki H., Chernak J.M., Roth G.S. Application of gene therapy to treat age-related loss of dopamine D2 receptor. Exp Gerontol 1998, 33:793-804.
85. Gerfen C.R., Surmeier D.J. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 2010.
86. Galvan A., Wichmann T. Pathophysiology of parkinsonism. Clin Neurophysiol 2008, 119:1459-1474.
87. Nambu A. A new dynamic model of the cortico-basal ganglia loop. Prog Brain Res 2004, 143:461-466.
88. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temino B., Mena-Segovia J., et al. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 2008, 64(Suppl. 2):S30-S46.
89. Tang J.K., Moro E., Mahant N., Hutchison W.D., Lang A.E., Lozano A.M., et al. Neuronal firing rates and patterns in the globus pallidus internus of patients with cervical dystonia differ from those with Parkinson's disease. J Neurophysiol 2007, 98:720-729.
90. Ward N.S., Frackowiak R.S. Age-related changes in the neural correlates of motor performance. Brain 2003, 126:873-888.
91. Mattay V.S., Fera F., Tessitore A., Hariri A.R., Das S., Callicott J.H., et al. Neurophysiological correlates of age-related changes in human motor function. Neurology 2002, 58:630-635.
92. Calautti C., Serrati C., Baron J.C. Effects of age on brain activation during auditory-cued thumb-to-index opposition: a positron emission tomography study. Stroke 2001, 32:139-146.
93. Wu T., Zang Y., Wang L., Long X., Li K., Chan P. Normal aging decreases regional homogeneity of the motor areas in the resting state. Neurosci Lett 2007, 423:189-193.
94. Ohashi S., Mori A., Kurihara N., Mitsumoto Y., Nakai M. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neurosci Lett 2006, 401:183-187.
95. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 2007, 26:56-65.
96. Adler C.H., Hentz J.G., Joyce J.N., Beach T., Caviness J.N. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism Relat Disord 2002, 9:103-110.
97. Markesbery W.R., Jicha G.A., Liu H., Schmitt F.A. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009, 68:816-822.
98. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991, 41:202-205.
99. Sossi V., de la Fuente-Fernandez R., Schulzer M., Adams J., Stoessl A.J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006, 129:1050-1058.
100. Nagayama H., Ueda M., Kumagai T., Tsukamoto K., Nishiyama Y., Nishimura S., et al. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson's disease. Parkinsonism Relat Disord 2011, 17:150-152.
101. Emborg M.E., Moirano J., Raschke J., Bondarenko V., Zufferey R., Peng S., et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 2009, 36:303-311.